Videos

Kristen Krysko, MD, on Newer vs Injectable Disease-Modifying Therapies for Initial Treatment of Pediatric MS

06/01/2020

In this video, Dr Krysko discusses the findings from her study on the real-world effectiveness of newer vs injectable disease-modifying therapies among pediatric patients with multiple sclerosis. This study was featured in the 2020 American Academy of Neurology Science Highlights. Read the transcript here.

For more videos like this, visit Neurology Consultant.

Reference:

Krysko K, Graves J, Rensel M, et al. Real-world effectiveness of initial treatment with newer versus injectable disease-modifying therapies in pediatric multiple sclerosis. Neurology. 2020;94(15 suppl.). https://n.neurology.org/content/94/15_Supplement/625

Kristen Krysko, MD, is a neurologist and multiple sclerosis/neuroimmunology clinical research fellow at the University of California, San Francisco.

Migraine CME Series

Module 8 – Implementing Shared Decision-Making and Developing Personalized Treatment Plans

Module 7 – Addressing Patient Barriers in the Prevention of Chronic Migraine

Module 6 – The Role of Nonpharmacologic Treatment Approaches for the Prevention of Chronic Migraine

Module 5 – Pharmaceutical Treatments for Chronic Migraine Prophylaxis

Module 4 - New Therapeutic Targets in the Prevention of Chronic Migraine

Module 3 – Avoiding Medication Overuse Headache

Module 2 - Quality-of-Life Concerns in Patients With Migraine

Module 1 – Caring for Patients With Migraine in the COVID-19 Era: Focus on Teleneurology

News

News

Moderate Physical Activity May Mitigate ALS Risk for Male Patients

07/25/2024

Brionna Mendoza ;

Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.

Male individuals who engage in...

07/25/2024

Neurology

News

Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy

07/23/2024

Jolynn Tumolo ;

The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.

The US Food and Drug...

07/23/2024

Neurology

News

Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults

07/22/2024

Evi Arthur ;

Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.

Chronic loneliness was...

07/22/2024

Neurology

a hand breaks a wooden human figurine in half

News

Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse

07/18/2024

Jolynn Tumolo ;

The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.

The calcitonin gene-related...

07/18/2024

Neurology

News

Pediatric Neurological Manifestations Tied to SARS-CoV-2 and MIS-C

07/16/2024

Evi Arthur ;

Children and adolescents with acute SARS-CoV-2 or multisystem inflammatory syndrome (MIS-C) could be at high risk for long-term impairment and severe neurological manifestations and may benefit from further screening and intervention.

Children and adolescents with...

07/16/2024

Neurology

News

Acupuncture Improves Sleep, Quality of Life in Patients With Parkinson Disease

07/08/2024

Jolynn Tumolo ;

Sleep scores in patients with Parkinson disease (PD) improved a significant 29.65 points on the Parkinson Disease Sleep Scale after 4 weeks of acupuncture treatment, according to a study published in JAMA Network Open.

Sleep scores in patients with...

07/08/2024

Neurology

The US Food and Drug Administration headquarters sign.

News

FDA Rejects Parkinson Drug Due to 3rd-Party Manufacturing Concerns

07/02/2024

Brionna Mendoza ;

The US Food and Drug Administration (FDA) rejected AbbVie’s ABBV-95 (foscarbidopa/foslevodopa) last week, raising concerns via complete response letter (CRL) regarding the inspection of a third-party manufacturer listed in the drug...

The US Food and Drug...

07/02/2024

Neurology

News

Novel AD Treatment Approach Shows Promise in First Human Trial

06/25/2024

Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.

Exploratory outcomes from a...

06/25/2024

Psych Congress Network

News

ADHD Linked With Hiked Risk of Lewy Body Disease

06/25/2024

Attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of Lewy Body disease (LBD), according to results from a recent prospective observational cohort study published in The American Journal of Geriatric...

Attention-deficit/hyperactivity...

06/25/2024

Psych Congress Network

News

Drug Trial Shows Cognitive Impact of Huntington Disease, but Analysts Express Caution

06/24/2024

Scores on a cognitive battery showed a statistically significant difference in patients with Huntington disease and healthy control subjects at baseline in a phase 2 study involving the dalzanemdor, an investigational NMDA receptor positive...

Scores on a cognitive battery...

06/24/2024

Neurology

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

11/12/2020

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 

Emerging Treatments for Early...

11/12/2020

Neurology

Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology

11/12/2020

Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series

Early Alzheimer’s Disease...

11/12/2020

Neurology

Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

11/12/2020

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...

Emerging Treatments for Early...

11/12/2020

Neurology

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease

11/10/2020

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 

Current Treatment Limitations...

11/10/2020

Neurology

Kristen Krysko, MD, on Newer vs Injectable Disease-Modifying Therapies for Initial Treatment of Pediatric MS

Migraine CME Series

News

Alzheimer's Disease CME Series

Specialties

Events

Year Round Education

HMP Global Products